This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

ViVEXX Carotid Revascularization Trial (VIVA)

This study has been completed.
Information provided by (Responsible Party):
C. R. Bard Identifier:
First received: January 2, 2007
Last updated: January 17, 2017
Last verified: January 2017
To evaluate the safety and efficacy of the Bard ViVEXX Carotid Stent and Emboshield BareWire Rapid Exchange Embolic Protection System in the treatment of extracranial carotid artery stenosis in patients at high risk for carotid endarterectomy.

Condition Intervention Phase
Carotid Artery Stenosis Device: Carotid Artery Stenting Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The ViVEXX Carotid Revascularization Trial (VIVA) for High Surgical Risk Patients With Extracranial Carotid Artery Stenosis Using the Bard ViVEXX Carotid Stent and Emboshield BareWire Rapid Exchange Embolic Protection System

Further study details as provided by C. R. Bard:

Primary Outcome Measures:
  • Percentage of Patients Experiencing Major Adverse Events (MAE) [ Time Frame: 365 days from implantation ]
    A composite of major adverse events (MAE) including any death, any stroke and/or myocardial infarction occurring during the first 30 days post-procedure and ipsilateral stroke between 31 and 365 days post procedure.

Secondary Outcome Measures:
  • Number of Participants Experiencing Target Lesion Revascularization(s) (TLR) [ Time Frame: 12 months from implantation ]
    Number of participants experiencing a Target lesion revascularization(s) up to 12 months after implantation

  • Number of Patients Experiencing Access Site Complications [ Time Frame: 30 days following implantation ]
    Access site complications requiring blood transfusion (> 1 unit) or open surgical repair.

  • Number of Participants Experiencing Stroke Related Neurologic Deficit [ Time Frame: 30 days from implantation ]
    Number of participants experiencing stroke related neurologic deficit persisting at 30 days and attributed to the index procedure.

  • Number of Participants Experiencing Device Success [ Time Frame: at time of implantation ]
    Number of participants with successful delivery and deployment of device with <50% residual stenosis.

  • Number of Participants Experiencing Lesion Success [ Time Frame: at time of implantation ]
    number of participants experiencing achievement of <50% final residual diameter stenosis in the stented segment using the VIVEXX Carotid Stent and the Emboshield Embolic Protection System.

  • Number of Participants Experiencing Restenosis [ Time Frame: 12 months after implantation ]
    Number of participants experiencing Restenosis following placement of the ViVexx Carotid Stent.

Enrollment: 407
Study Start Date: October 2005
Study Completion Date: March 2010
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: stent placement in the carotid artery
placement of a bare metal stent for treatment of carotid artery stenosis
Device: Carotid Artery Stenting
placement of a bare metal stent at sites of stenosis in the carotid artery
Other Name: CAS

Detailed Description:
Patients with clinically significant stenosis within the common and/or internal carotid artery who are at high risk for carotid endarterectomy and are amenable to percutaneous treatment including embolic protection, balloon angioplasty and the carotid stent placement.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient has a symptomatic or asymptomatic carotid artery stenosis that meets one of the following criteria:

    • Symptomatic: > than or = to 50% carotid stenosis by angiography and a history of non-disabling stroke, transient ischemic attack (TIA) in the hemisphere supplied by the target vessel within 180 days of the procedure.
    • Asymptomatic: > than or = to 80% carotid stenosis by angiography without neurological symptoms.
  • High risk for carotid endarterectomy: anatomical and co-morbid.

Exclusion Criteria:

  • History of symptoms of stroke or TIA within 24 hours of the procedure
  • Extensive or diffuse atherosclerotic disease
  • Severe vascular tortuosity or anatomy that would preclude the safe introduction of the device
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00417963

Sponsors and Collaborators
C. R. Bard
Principal Investigator: Kenneth Rosenfield, MD Massachusetts General Hospital
  More Information

Responsible Party: C. R. Bard Identifier: NCT00417963     History of Changes
Other Study ID Numbers: BPV-VX-1502
Study First Received: January 2, 2007
Results First Received: April 16, 2011
Last Updated: January 17, 2017

Keywords provided by C. R. Bard:

Additional relevant MeSH terms:
Constriction, Pathologic
Carotid Stenosis
Pathological Conditions, Anatomical
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on August 18, 2017